All figures reflect the 2026 Medicare plan year and come from CMS and KFF published data; this article is educational and is not insurance or medical advice.
TL;DR — Quick Verdict
- Premium is the smallest variable. Tier placement of your specific drugs drives 70–90% of the cost difference between two plans with similar premiums.
- The 2026 standard Part D deductible is $615 and the annual out-of-pocket cap is $2,100. KFF reports 78% of PDP enrollees are in a plan charging the full $615 deductible, and those enrollees pay an average premium of just $22 per month.
- Zero-deductible PDPs exist but cost an average of $127 per month — roughly $1,260 more per year in premium than the low-premium plans, to avoid a $615 deductible.
- Comparison result: for a beneficiary on two brand-name maintenance drugs, a $0-premium plan that places both on Tier 4 (median 34% coinsurance in PDPs) typically costs more per year than a $40-premium plan placing them on Tier 3 (median 25%).
- Recommendation: run your exact drug list, doses, and preferred pharmacy through the Medicare Plan Finder every single year. Formularies changed materially for 2026 as PDP count fell to roughly 360 nationwide.
Roughly 18.6 million people hold a stand-alone Part D drug plan, and most of them will re-enroll this fall without opening a formulary. That is an expensive habit. KFF’s 2026 analysis found that only 4% of PDP enrollees are in a plan charging no drug deductible — down from 15% a year earlier — while 78% now face the full $615 standard deductible. The plans did not simply get pricier. They restructured what they cover and where each drug sits.
Two enrollees in the same ZIP code, taking the same two medications, can pay a difference of more than $2,000 across a calendar year depending on whether their plan filed those drugs on Tier 3 or Tier 4. Wellcare, SilverScript, and UnitedHealthcare all shifted tier assignments for 2026, and Elevance exited the stand-alone market entirely. This analysis shows the actual cost math behind formulary tiers, models three real spending scenarios against the $2,100 cap, and identifies which enrollees should switch plans versus stay put. Premium comparison is the least useful thing you can do during annual enrollment switching rules.
2026 Part D Cost Structure: The Four Numbers That Set Your Floor
Four federal parameters govern every Part D plan in the country. Plans can be more generous than these numbers; none can be less generous. Knowing them tells you immediately whether a plan is basic, enhanced, or simply overpriced.
The redesign finished in 2025 collapsed the old four-phase benefit — deductible, initial coverage, coverage gap, catastrophic — into three phases. The donut hole no longer exists. In its place sits a hard annual out-of-pocket ceiling, above which the enrollee pays nothing for covered drugs. That single change altered which plan type wins for high-cost patients.
Source: Centers for Medicare & Medicaid Services, 2026 Part D parameters and Medicare Parts A & B premiums fact sheet (verify at cms.gov); specialty tier threshold per KFF 2026 Part D cost-sharing analysis.
Notice what the $2,100 cap does to the arithmetic. A beneficiary on a single specialty drug at 25% coinsurance hits the ceiling within roughly two months and pays nothing thereafter. For that person, the plan’s premium and deductible are the only variables that matter, because the cap equalizes everything above it. For someone on four generics costing $40 a month total, the cap is irrelevant and the deductible is everything.
How Formulary Tiers Actually Determine What You Pay
Nearly every Part D plan uses a five-tier formulary: preferred generics, generics, preferred brands, non-preferred drugs, and specialty drugs. The tier a drug lands on is a business decision made by the plan sponsor, driven by manufacturer rebate negotiations — not by clinical category. The same molecule can sit on Tier 3 with one carrier and Tier 4 with another.
That distinction carries real money. KFF’s 2026 data shows the median coinsurance rate for preferred brands is 25% in PDPs and 21% in MA-PDs, while non-preferred drugs carry median coinsurance of 34% in PDPs and 38% in MA-PDs. Virtually all PDP enrollees — 97% for preferred brands and 100% for non-preferred drugs — face coinsurance rather than a flat copayment, meaning your cost floats with the drug’s list price rather than sitting at a predictable dollar figure.
Median cost-sharing rates from KFF, Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026. Dollar figures are original calculations applying median rates to a hypothetical $400 monthly list price.
Run that difference across a year. A drug on Tier 3 at 25% costs $1,200 annually; the same drug on Tier 4 at 34% costs $1,632. Add the $615 deductible and the Tier 4 enrollee reaches the $2,100 cap in month nine, while the Tier 3 enrollee reaches it in month eleven. Both eventually stop paying — but the Tier 4 enrollee handed over more cash earlier in the year, and if the drug is dropped from the formulary mid-year, none of it counts.
Plans that waive part or all of the deductible are permitted to set specialty tier coinsurance above 25%, which is why most MA-PD plans show a higher specialty rate. That trade-off matters when weighing Advantage versus Original Medicare for chronic conditions.
Stand-Alone PDP vs MA-PD Drug Coverage: Which Is Better for a Two-Drug Retiree?
Premium comparison between these two structures is misleading by design. Medicare Advantage sponsors use federal rebate dollars to buy down the drug portion of their premium, which is why KFF puts the average Part D portion of an MA-PD premium at $8 per month against an average of $36 for stand-alone PDPs in 2026. Nothing about that $28 gap tells you which plan covers your medications better.
Consider a specific case. A 71-year-old in a metro county takes rosuvastatin (generic, Tier 1 nearly everywhere) and a branded DOAC anticoagulant with a $560 monthly list price. The PDP option charges $36 per month with the standard $615 deductible and places the DOAC on Tier 3 at 25%. The MA-PD option charges $8 per month for drugs with a $615 deductible and places the same DOAC on Tier 4 at 38%.
Original scenario modeling by Real Cost Report using 2026 federal parameters from CMS (verify at cms.gov) and median tier coinsurance rates from KFF. Figures are modeled, not measured; actual list prices and tier placements vary by plan and pharmacy.
Verdict
For this two-drug retiree, the MA-PD wins on drug spending by $336 — but only because the $2,100 cap absorbs the worse tier placement. The higher Tier 4 coinsurance actually accelerates the enrollee to the ceiling. That result flips entirely for someone whose drug spending never approaches $2,100: a beneficiary on $150 per month of Tier 3 brands never hits the cap, and the 38% versus 25% coinsurance gap costs them roughly $234 more per year in the MA-PD with no offsetting protection. Choose the MA-PD drug benefit only after confirming the full picture on medical cost sharing and network, not on the drug math alone.
The cap changes who benefits from what. High spenders become nearly indifferent to tier placement and should optimize on premium and deductible. Moderate spenders — the $800 to $1,800 annual range — are the group where formulary tier selection produces the largest dollar swing, because they pay every coinsurance dollar without ever reaching protection. That group should also review comparing Advantage plans beyond premium before committing.
The Premium-Deductible Trade-Off Most Enrollees Get Backward
Zero-deductible plans feel safer. The pricing says otherwise. KFF found that the 4% of PDP enrollees in a plan charging no drug deductible pay an average premium of $127 per month, while the 78% in a plan charging the full $615 deductible pay an average premium of $22 per month.
Do that subtraction. The zero-deductible enrollee pays $1,524 per year in premium against $264 for the standard-deductible enrollee — a gap of $1,260 to eliminate a $615 obligation. The plan is charging roughly $2.05 in premium for every $1.00 of deductible relief. No spending pattern makes that arithmetic work, which is why only 4% of the market buys it.
Enhanced plans occupy the middle. KFF reports 58% of PDP enrollees (10.8 million people) hold enhanced plans at an average premium of $39 per month, against $31 for the 42% (7.8 million) in basic plans. The $8 monthly gap — $96 annually — buys either lower cost sharing, a reduced deductible, or broader formulary coverage. Whether that is worth it depends entirely on which of the three the specific plan delivers, and only the formulary document tells you.
Anyone assessing the premium side of this equation should also confirm their surcharge exposure, since Part D IRMAA is billed separately from the plan premium and paid directly to Medicare. Details on that mechanism sit in our analysis of IRMAA surcharge rules and reduction requests.
Five Formulary Mistakes That Cost Real Money
Errors in Part D selection are consistent and predictable. Each one below has a measurable dollar consequence.
Mistake 1: Comparing premiums instead of total annual cost
Consequence: A $0-premium plan with your drugs on Tier 4 can cost $400 to $900 more per year than a $40-premium plan with the same drugs on Tier 3. Correct action: Enter every drug, dose, and quantity into the Medicare Plan Finder and sort by estimated annual cost, not monthly premium.
Mistake 2: Ignoring preferred pharmacy designation
Consequence: Filling at a standard rather than preferred network pharmacy can raise a copayment by 50% or more on identical medication. Correct action: Confirm which specific pharmacies carry preferred status under the plan you are considering, then verify that one is within reasonable driving distance.
Mistake 3: Assuming last year’s formulary carries forward
Consequence: Plans dropped drugs and shifted tiers substantially for 2026 as the PDP field contracted to roughly 360 plans nationwide, down from 464 in 2025. A drug covered on Tier 2 last year may sit on Tier 4 now. Correct action: Read the Annual Notice of Change every September and check each drug individually.
Mistake 4: Overlooking prior authorization and step therapy flags
Consequence: A drug can appear on the formulary at an attractive tier and still be blocked pending paperwork, forcing weeks of delay or full retail payment. Correct action: In the Plan Finder drug list, check for PA, ST, and QL notations beside each medication before enrolling.
Mistake 5: Skipping Part D entirely because you take no drugs
Consequence: The late enrollment penalty equals 1% of the $38.99 national base beneficiary premium for each uncovered month, added permanently to your premium. Thirty uncovered months produces a surcharge of roughly $11.70 per month for life, indexed annually. Correct action: Enroll in the lowest-premium compliant plan available even with zero prescriptions. The full penalty structure appears in our guide to enrollment deadlines and late penalty costs.
Who Should Switch Plans This Year — and Who Should Not
Switching carries a real cost in time and risk of error. The following conditions justify it.
Switch if any of these apply. Your Annual Notice of Change moved one of your drugs to a higher tier or removed it. Your plan added prior authorization to a medication you already take. Your current plan’s deductible rose to the full $615 while comparable plans in your county charge less. Your preferred pharmacy left the network. You started a new brand-name medication mid-year that your formulary does not cover well. Any of these individually can move annual cost by several hundred dollars.
Stay put if all of these hold. Every drug you take remained on the same tier. Your total projected annual drug spending falls below $500, where tier differences produce trivial dollar swings. Your plan’s premium changed by less than $5 per month. Under those conditions the expected savings from switching rarely exceed $100, and the risk of a coverage gap during transition is a real cost of its own.
Beneficiaries with income above $109,000 individually or $218,000 jointly face an additional consideration. Part D IRMAA in 2026 ranges from $14.50 to $91.00 per month across five tiers and is added on top of whatever the plan itself charges. That surcharge applies identically regardless of which plan you pick, so it does not change the comparison — but it does mean a high earner comparing a $22 plan against a $39 plan is really comparing $113 against $130 at the top bracket. The same income thresholds drive the Part B premium, IRMAA tiers, and appeals process.
People holding a Medigap policy face a different calculus than Advantage enrollees, since the drug plan is a separate purchase entirely. Our comparison of Medigap vs Medicare Advantage annual cost covers where the stand-alone PDP fits into that structure, and the Supplement Plan G vs Plan N cost comparison addresses the medical side of the same decision. Retirees still holding workplace coverage should verify creditable status through our review of Medicare coordination with employer coverage before dropping it.
Frequently Asked Questions
Does the $2,100 out-of-pocket cap include my monthly premium?
No. The 2026 cap of $2,100 counts your deductible, copayments, and coinsurance on covered Part D drugs. Premiums do not count toward it, and neither do costs for drugs excluded from your plan’s formulary or purchased outside the network. A beneficiary paying $36 per month in premium and reaching the cap therefore spends $2,532 total across the year, per CMS Part D benefit parameters.
Can my plan move a drug to a higher tier in the middle of the year?
Plans can make certain mid-year formulary changes, though CMS restricts the timing and requires advance notice for most negative changes affecting current users. If a drug you already take is moved or removed, you can request a formulary exception, and plans must maintain coverage of all drugs selected for Medicare drug price negotiation, including every dosage form and strength.
How many Part D plans can I actually choose from?
KFF reports that beneficiaries in each state have a choice of between 8 and 12 stand-alone prescription drug plans in 2026, plus Medicare Advantage plans with drug coverage. That is down sharply from prior years — roughly 360 PDPs nationwide against 464 in 2025 — following market exits including Elevance’s full withdrawal from the stand-alone segment.
Why is my insulin capped at $35 but my other drugs are not?
Federal law caps insulin cost sharing separately from the general benefit structure. For 2026, the amount is the lower of $35 per month or 25% of the Maximum Fair Price for that product, and the Part D deductible does not apply — you get the capped price starting in January. No comparable per-drug cap exists for other medication classes; they run through the standard deductible and tier coinsurance until the $2,100 ceiling.
How We Researched This Article
Every federal benefit parameter cited here — the $615 standard deductible, the $2,100 annual out-of-pocket cap, the $38.99 national base beneficiary premium, the $950 specialty tier threshold, and the $35 insulin cost-sharing cap — was verified against 2026 Centers for Medicare & Medicaid Services published parameters rather than drawn from prior-year recall. CMS releases these figures in its annual Part D benefit parameters guidance and its Medicare Parts A & B premiums and deductibles fact sheet, both available at cms.gov.
Plan-level distributions — average premiums by plan type, the share of enrollees facing each deductible level, median coinsurance rates by formulary tier, and the count of available plans per state — come from KFF’s 2026 Part D enrollment and cost-sharing analysis, which is built on CMS plan landscape and enrollment files. Where KFF reports enrollment-weighted figures, we labeled them as such rather than presenting them as simple plan averages, because the two differ materially in a market where a small number of large plans hold most enrollees. Additional context on the benefit redesign and drug price negotiation timing came from KFF’s Part D program snapshot.
The two cost scenarios in this article are modeled, not measured. We applied verified 2026 federal parameters and KFF median tier coinsurance rates to hypothetical drug list prices and disclosed that construction in each table caption. No named plan’s specific formulary was used to generate those dollar figures, because tier placement varies by carrier, contract, and county, and any single-plan example would mislead readers outside that plan’s service area.
Limitations worth stating plainly: median coinsurance rates describe the middle of a distribution, not any individual plan, and actual out-of-pocket cost depends on negotiated drug prices that plans do not publish uniformly. Drug list prices used in modeling are illustrative. County-level premium and formulary data was outside the scope of this analysis; readers must run their own drug list through the official Medicare Plan Finder at medicare.gov for a personalized figure. Research was last conducted July 2026.
All figures were verified against named primary sources before publication.